keyword
MENU ▼
Read by QxMD icon Read
search

Eye anti-VEGF

keyword
https://www.readbyqxmd.com/read/29148027/sequential-tissue-plasminogen-activator-pneumatic-displacement-and-anti-vegf-treatment-for-submacular-hemorrhage
#1
Handan Bardak, Yavuz Bardak, Yeşim Erçalık, Burak Erdem, Gökhan Arslan, Semrin Timlioglu
PURPOSE: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH). METHODS: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day...
November 4, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/29137019/optical-coherence-tomography-angiography-in-patients-with-diabetic-retinopathy-treated-with-anti-vegf-intravitreal-injections-case-report
#2
Katarzyna Michalska-Małecka, Anna Heinke Knudsen
PURPOSE: To present optical coherence tomography angiography (OCTA) features in patients with diabetic retinopathy (DR) at the baseline and in response to treatment with anti-VEGF intravitreal injections. To investigate the role of OCTA in management of patients with DR. METHODS: Retrospective case series showing primary outcomes of 3 patients with DR and diabetic macular edema. Patients were injected intravitreally a loading phase of 3 monthly 2.0 mg aflibercept, followed by 2 injections bimonthly (5 injections in total)...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29134820/pharmacokinetics-of-intravitreal-anti-vegf-drugs-in-vitrectomized-versus-non-vitrectomized-eyes
#3
Magdalena Edington, Julie Connolly, Ngaihang Victor Chong
Introduction The review aims to discuss effects of vitrectomy on pharmacokinetics of anti-vascular endothelial growth factor (anti-VEGF) agents, and attempt to provide treatment guidance. Areas Covered An Embase search was conducted using the terms 'anti-VEGF', 'pegaptanib', 'ranibizumab', 'bevacizumab', 'aflibercept', 'pharmacokinetics', 'half-life', 'clearance', 'metabolism', 'vitrectomy', 'vitrectomized'. Published data regarding the pharmacokinetic properties of the above drugs and the effect of vitrectomy in animal and human eyes was reviewed...
November 14, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29131696/risk-factors-for-discontinuation-of-treatment-for-neovascular-age-related-macular-degeneration
#4
Inger Westborg, Aldana Rosso
PURPOSE: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD). METHODS: Data from the Swedish Macula Register and the Skåne Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14 months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree...
November 13, 2017: Ophthalmic Epidemiology
https://www.readbyqxmd.com/read/29127949/effect-of-adding-dexamethasone-to-continued-ranibizumab-treatment-in-patients-with-persistent-diabetic-macular-edema-a-drcr-network-phase-2-randomized-clinical-trial
#5
Raj K Maturi, Adam R Glassman, Danni Liu, Roy W Beck, Abdhish R Bhavsar, Neil M Bressler, Lee M Jampol, Michele Melia, Omar S Punjabi, Hani Salehi-Had, Jennifer K Sun
Importance: Some eyes have persistent diabetic macular edema (DME) following anti-vascular endothelial growth factor (anti-VEGF) therapy for DME. Subsequently adding intravitreous corticosteroids to the treatment regimen might result in better outcomes than continued anti-VEGF therapy alone. Objective: To compare continued intravitreous ranibizumab alone with ranibizumab plus intravitreous dexamethasone implant in eyes with persistent DME. Design, Setting, and Participants: Phase 2 multicenter randomized clinical trial conducted at 40 US sites in 129 eyes from 116 adults with diabetes between February 2014 and December 2016...
November 11, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29117316/vitreous-fibronectin-and-fibrinogen-expression-increased-in-eyes-with-proliferative-diabetic-retinopathy-after-intravitreal-anti-vegf-therapy
#6
Qiaoling Wei, Ting Zhang, Rui Jiang, Qing Chang, Yanqiong Zhang, Xin Huang, Xing Gao, Hong Jin, Gezhi Xu
Purpose: To evaluate vitreous humor (VH) protein expression profiles in patients with proliferative diabetic retinopathy (PDR), with and without intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) before vitrectomy. Methods: We enrolled consecutive PDR patients who needed pars plana vitrectomy (PPV) with or without IVI or pan-retinal photocoagulation (PRP). Visual acuity, duration, and treatment of diabetes mellitus, ocular treatment history, and fundus examinations were recorded...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29117277/naringenin-eye-drops-inhibit-corneal-neovascularization-by-anti-inflammatory-and-antioxidant-mechanisms
#7
Ana P M T Oguido, Miriam S N Hohmann, Felipe A Pinho-Ribeiro, Jefferson Crespigio, Talita P Domiciano, Waldiceu A Verri, Antonio M B Casella
Purpose: To investigate the effect of naringenin eye drops in corneal neovascularization induced by alkali (1 N NaOH) burn in mice. Methods: Corneal neovascularization in the right eye of male Swiss mice was induced by alkali. Treatment with naringenin eye drops (0.08-80 μg; 8 μL of 0.01-10 g/L solution) or vehicle (saline) started 2 days before corneal neovascularization was induced and was performed twice a day. Mice were treated up until the time animals were euthanized and cornea tissue was collected for testing, which was 2, 4, and 6 hours after alkali stimulus for cytokine and antioxidant capacity measurements, and 3 and/or 7 days after alkali stimulus for the assessment of corneal epithelial thickness and neovascularization, neutrophil, and macrophage recruitment, and vascular endothelial growth factor (Vegf), platelet-derived growth factor (Pdgf), matrix metalloproteinase-14 (Mmp14), and pigment epithelium-derived factor (Pedf) mRNA expression...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29109896/outcomes-of-intravitreal-dexamethasone-implant-in-the-treatment-of-recalcitrant-diabetic-macular-edema
#8
Dorukcan Akıncıoğlu, Murat Küçükevcilioğlu, Ali Hakan Durukan, Seçkin Aykaş, Önder Ayyıldız, Fazıl Cüneyt Erdurman
Objectives: To investigate the efficacy and safety of intravitreal dexamethasone (OZURDEX®) implantation in patients with recalcitrant diabetic macular edema. Materials and Methods: This is a retrospective non-randomized study of patients who underwent intravitreal dexamethasone implantation for recalcitrant diabetic macular edema. Main outcome measures included changes in best corrected visual acuity (BCVA), central macular thickness (CMT), and incidence of ocular side effects...
October 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29104958/prediction-of-anti-vegf-response-in-diabetic-macular-edema-after-1-injection
#9
Ankoor R Shah, Yoshihiro Yonekawa, Bozho Todorich, Lily Van Laere, Rehan Hussain, Maria A Woodward, Ashkan M Abbey, Jeremy D Wolfe
Purpose: With multiple anti-vascular endothelial growth factor and steroid therapies available for diabetic macular edema (DME), there is a need for early determination of the best treatment for a particular patient to prevent irreversible vision loss from chronic DME. In this study, we classify patients as responders or non-responders to anti-vascular endothelial growth factor (VEGF) monotherapy in the treatment of DME after a single anti-VEGF injection. Methods: The study was designed as a single center, retrospective, interventional case series...
May 2017: J Vitreoretin Dis
https://www.readbyqxmd.com/read/29099501/efficacy-and-timing-of-adjunctive-therapy-in-the-anti-vegf-treatment-regimen-for-macular-oedema-in-retinal-vein-occlusion-12-month-real-world-result
#10
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
November 3, 2017: Eye
https://www.readbyqxmd.com/read/29094168/systemic-biodistribution-and-intravitreal-pharmacokinetic-properties-of-bevacizumab-ranibizumab-and-aflibercept-in-a-nonhuman-primate-model
#11
John Byron Christoforidis, Karen Briley, Katherine Binzel, Prayna Bhatia, Lai Wei, Krishan Kumar, Michael Vinzenz Knopp
Purpose: To determine the intravitreal pharmacokinetic properties and to study the systemic biodistribution characteristics of I-124-labeled bevacizumab, ranibizumab, and aflibercept with positron emission tomography-computed tomography (PET/CT) imaging in a nonhuman primate model. Methods: Three groups with four owl monkeys per group underwent intravitreal injection with 1.25 mg/0.05 mL I-124 bevacizumab, 0.5 mg/0.05 mL I-124 ranibizumab, or 2.0 mg/0.05 mL I-124 aflibercept in the right eye of each subject...
November 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29093970/two-year-outcome-of-aflibercept-in-patients-with-pigment-epithelial-detachment-due-to-neovascular-age-related-macular-degeneration-namd-refractory-to-ranibizumab
#12
Thi Ha Chau Tran, Stéphane Dumas, Florence Coscas
Purpose: To evaluate the response of intravitreal aflibercept injection (IAI) in eyes with detachment of retinal pigment epithelium (DEP) secondary to nAMD refractory to monthly ranibizumab. Patients and Methods: This is a retrospective, multicenter study. All patients received 3 IAI then treated as needed every 4 weeks for 12 months. During the second year, the eyes were treated with a treat- and-extend regimen. Results: Forty-four eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29079450/the-expanded-spectrum-of-perifoveal-exudative-vascular-anomalous-complex
#13
Riccardo Sacconi, K Bailey Freund, Lawrence A Yannuzzi, Rosa Dolz-Marco, Eric Souied, Vittorio Capuano, Oudy Semoun, Nopasak Phasukkijwatana, David Sarraf, Adriano Carnevali, Lea Querques, Francesco Bandello, Giuseppe Querques
PURPOSE: to expand our understanding of the uncommon entity, referred to as perifoveal exudative vascular anomalous complex (PEVAC) by describing multimodal imaging findings, including optical coherence tomography-angiography (OCT-A). DESIGN: Retrospective cohort study. METHODS: Patients diagnosed with PEVAC were identified at 4 retina referral centers worldwide and underwent complete ophthalmologic examination including structural OCT, OCT-A, fluorescein angiography (FA) and indocyanine green angiography (ICGA)...
October 24, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29076303/anti-vegf-therapy-for-diabetic-eye-diseases
#14
Bobak Bahrami, Thomas Hong, Mark C Gilles, Andrew Chang
Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working-age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision-threatening disease. There is now strong evidence supporting intravitreal anti-VEGF therapy as first line in the management of sight-threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti-VEGF drugs for proliferative DR...
October 26, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29074495/outcome-of-anti-vascular-endothelial-growth-factor-therapy-for-neovascular-age-related-macular-degeneration-in-real-life-setting
#15
Maria Kataja, Pekko Hujanen, Heini Huhtala, Kai Kaarniranta, Anja Tuulonen, Hannele Uusitalo-Jarvinen
AIMS: To evaluate outcome of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related macular degeneration (nAMD) in the real-life setting and to compare incidence of ocular serious adverse events (SAE) after injections administered by nurses and physicians. METHODS: Retrospective, single-centre study. Medical records of patients receiving anti-VEGF treatment for nAMD between 2008 and 2013 with three-loading-dose regimen were evaluated...
October 26, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29069705/-the-impact-of-multiple-intravitreal-anti-vegf-injections-on-intraocular-pressure
#16
Ioannis Lamprakis, Margarita Georgieva Todorova, Matthias Grüb, Torsten Schlote
Background To evaluate the possible effects of multiple intravitreal anti-vascular endothelial growth factor (VEGF) injections on intraocular pressure (IOP). Methods This study included 50 eyes of 50 patients who underwent multiple (≥ 10 injections) intravitreal anti-VEGF injections in one eye with age-related macular degeneration, diabetic macular edema or retinal vein occlusion. IOP was recorded after every injection on the first postoperative day. IOP > 21 mmHg was regarded as abnormal. For statistical analysis, the IOP was correlated with the number of injections...
October 25, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29061629/a-longitudinal-study-to-assess-the-frequency-and-cost-of-antivascular-endothelial-therapy-and-inequalities-in-access-in-england-between-2005-and-2015
#17
William Hollingworth, Tim Jones, Barnaby C Reeves, Tunde Peto
OBJECTIVES: High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in access. DESIGN: Longitudinal study using Hospital Episode Statistics (2005/2006 to 2014/2015) and hospital prescribing cost reports (2008/2009 to 2015/2016). We used Poisson regression to estimate standardised rates and explore temporal and geographical variations...
October 22, 2017: BMJ Open
https://www.readbyqxmd.com/read/29057640/the-armour-study-anti-vegf-in-neovascular-amd-our-understanding-in-a-real-world-indian-setting
#18
Nimesh Jain, Naresh Kumar Yadav, Chaitra Jayadev, Priya Srinivasan, Ashwin Mohan, Bhujang K Shetty
PURPOSE: The aim of our study was to share our experience with anti‒vascular endothelial growth factor (anti-VEGF) injections in the treatment of neovascular age-related macular degeneration (nAMD) in a real-world setting. DESIGN: A retrospective, observational study. METHODS: Patients of Indian origin with nAMD receiving anti-VEGF with a minimum follow-up of 12 months were enrolled in this study. In group 1, patients were treated on a pro re nata (PRN) basis; in group 2, patients received a loading dose (3 injections) and were then treated on a PRN basis...
October 23, 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29044068/needle-stick-injuries-in-a-tertiary-eye-care-hospital-incidence-management-outcomes-and-recommendations
#19
Ekta Rishi, B Shantha, Abhinav Dhami, Pukhraj Rishi, Hannah C Rajapriya
PURPOSE: The purpose of this study is to assess the incidence, management, and outcomes for needle stick injuries (NSIs) in a tertiary eye-care hospital and provide appropriate recommendations for its prevention. METHODS: This was a retrospective database review of NSI recorded between 2010 and 2015 at a tertiary eye care center. All staff members who had NSI were managed with standard treatment protocol. The mode, location, health-care workers affected and/or at risk for NSI were analyzed...
October 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29040008/analysis-of-the-clinical-profile-and-management-of-inflammatory-choriodal-neovascular-membranes-in-uveitic-eyes-a-study-from-a-tertiary-referral-center
#20
Sudha Ganesh, Arshee Ahmed, Jyotirmay Biswas
PURPOSE: To analyze clinical profile and management of inflammatory choroidal neovascularization (CNV) seen at a referral uveitis clinic. METHODS: Records of patients with uveitis and inflammatory CNV from January 1989 to April 2012 were retrieved and the data was analyzed. RESULTS: Forty-nine eyes of 43 patients were included. Mean age at presentation was 35.81 years. Eighteen eyes (36.7%) had infective etiology and 31 eyes (63.2%) had non-infective etiology...
October 17, 2017: Ocular Immunology and Inflammation
keyword
keyword
36614
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"